Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 1/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.34 |
| ▸ | JAK2 | O60674 | 3/20 | 0.33 |
| ▸ | JAK1 | P23458 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | RET | P07949 | 1/20 | 0.32 |
| ▸ | TTK | P33981 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3356340 | 0.84 | ALDH1A1 (0.38) | CTSKGPR119ALDH1A1GLAHTT | |
| SCHEMBL31105862 | 0.78 | ROCK2 (0.34) | GPR119HTTATM | |
| SCHEMBL6323000 | 0.78 | GPR119 (0.32) | CTSKGPR119ALDH1A1GLARET | |
| SCHEMBL31052456 | 0.77 | HSP90AA1 (0.38) | GPR119HTTATM | |
| SCHEMBL22206161 | 0.77 | ROCK2 (0.34) | GPR119HTTATM | |
| SCHEMBL4699798 | 0.77 | ROCK2 (0.36) | GPR119ALDH1A1HTTATMKDM4E | |
| SCHEMBL4139863 | 0.76 | ALDH1A1 (0.38) | ALDH1A1GLAKDM4EHSD17B10 | |
| SCHEMBL6323004 | 0.75 | GPR119 (0.33) | GPR119 | |
| SCHEMBL22875387 | 0.75 | GPR119 (0.46) | GPR119 | |
| SCHEMBL13583956 | 0.74 | GPR119 (0.36) | GPR119RETTTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4717317-A2 | N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION | C4 Therapeutics, Inc. (US) | 2026-04-01 | — | — | EP | disclosed |
| EP-3641762-B1 | N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION | C4 THERAPEUTICS INC (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20260015362-A1 | N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2026-01-15 | — | — | US | disclosed |
| US-12441740-B2 | N/O-linked degrons and degronimers for protein degradation | C4 THERAPEUTICS, INC. (US) | 2025-10-14 | — | — | US | disclosed |
| US-20250101037-A1 | N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2025-03-27 | — | — | US | disclosed |
| US-12180225-B2 | N/O-linked degrons and degronimers for protein degradation | C4 THERAPEUTICS, INC. (US) | 2024-12-31 | — | — | US | disclosed |
| CN-118440096-A | Degradation stator and degradation determinant for N/O-ligation of protein degradation | C4医药公司 | 2024-08-06 | — | — | CN | disclosed |
| US-20230279023-A1 | N/O-Linked Degrons and Degronimers for Protein Degradation | C4 THERAPEUTICS, INC. (US) | 2023-09-07 | — | — | US | disclosed |
| US-20230279023-A1 | N/O-Linked Degrons and Degronimers for Protein Degradation | C4 THERAPEUTICS, INC. (US) | 2023-09-07 | — | — | US | disclosed |
| US-20230279023-A1 | N/O-Linked Degrons and Degronimers for Protein Degradation | C4 THERAPEUTICS, INC. (US) | 2023-09-07 | — | — | US | disclosed |
| US-20230118497-A1 | PYRAZOLE-CONTAINING POLYCYCLIC DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-04-20 | — | — | US | disclosed |
| US-20230118497-A1 | PYRAZOLE-CONTAINING POLYCYCLIC DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-04-20 | — | — | US | disclosed |
| WO-2022258007-A1 | SALT AND CRYSTAL FORM OF PYRAZOLE-CONTAINING POLYCYCLIC DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翰森生物医药科技有限公司 | 2022-12-15 | — | — | WO | disclosed |
| EP-4074714-A1 | PYRAZOLE-CONTAINING POLYCYCLIC DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Shanghai Hansoh Biomedical Co., Ltd. (CN) | 2022-10-19 | — | — | EP | disclosed |
| US-11459335-B2 | N/O-linked Degrons and Degronimers for protein degradation | C4 THERAPEUTICS, INC. (US) | 2022-10-04 | — | — | US | disclosed |
| US-20200140456-A1 | N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2020-05-07 | — | — | US | disclosed |
| US-20200140456-A1 | N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2020-05-07 | — | — | US | disclosed |
| EP-3641762-A1 | N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION | C4 Therapeutics, Inc. (US) | 2020-04-29 | — | — | EP | disclosed |
| CN-110769822-A | N/O-linked degron and degron bodies for protein degradation | C4医药公司 | 2020-02-07 | — | — | CN | disclosed |
| WO-2018237026-A1 | N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2018-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12441740-B2 | N/O-linked degrons and degronimers for protein degradation | CRBN, CBL, STUB1 | CTSK 1851/4885GPR119 2204/4885JAK2 2161/4885 |
| US-20250101037-A1 | N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION | CRBN, CBL, STUB1 | CTSK 1851/4885GPR119 2204/4885JAK2 2161/4885 |
| US-12180225-B2 | N/O-linked degrons and degronimers for protein degradation | CRBN, CBL, STUB1 | CTSK 1851/4885GPR119 2204/4885JAK2 2161/4885 |
| US-20230118497-A1 | PYRAZOLE-CONTAINING POLYCYCLIC DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | P2RX3, P2RX7, P2RX4 | CTSK 2319/4885GPR119 145/4885JAK2 1935/4885 |
| US-20260015362-A1 | N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION | CRBN, CBLC, CBL | CTSK 3184/4885GPR119 1441/4885JAK2 1689/4885 |
| US-20230279023-A1 | N/O-Linked Degrons and Degronimers for Protein Degradation | CRBN, CBL, STUB1 | CTSK 1851/4885GPR119 2204/4885JAK2 2161/4885 |
| US-11459335-B2 | N/O-linked Degrons and Degronimers for protein degradation | CRBN, CBL, STUB1 | CTSK 1851/4885GPR119 2204/4885JAK2 2161/4885 |
| US-20200140456-A1 | N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION | CRBN, CBL, STUB1 | CTSK 1851/4885GPR119 2204/4885JAK2 2161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.